Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprvir and sofosbuvir in HIV/HCV coinfected patients with liver cirrhosis

Trial Profile

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprvir and sofosbuvir in HIV/HCV coinfected patients with liver cirrhosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Dolutegravir (Primary) ; Rilpivirine (Primary) ; Simeprevir; Sofosbuvir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 Dec 2016 New trial record
    • 20 Dec 2016 Results published in the Journal of Antimicrobial Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top